Aetna modified CPB 1069 for axatilimab-csfr (Niktimvo), effective September 26, 2025. Here's what billing teams need to do.
Aetna, a CVS Health company, updated Clinical Policy Bulletin 1069 covering axatilimab-csfr (Niktimvo) for chronic graft-versus-host disease (cGVHD). This policy governs reimbursement for HCPCS J9038 and the infusion administration codes CPT 96413 and 96415. If your team bills for cGVHD treatment in commercial plan patients, this coverage policy directly affects your precertification workflow and claim submission process.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna |
| Policy | Axatilimab-csfr (Niktimvo) — CPB 1069 |
| Policy Code | CPB 1069 |
| Change Type | Modified |
| Effective Date | September 26, 2025 |
| Impact Level | High |
| Specialties Affected | Hematology, Oncology, Bone Marrow Transplant, Infusion Centers |
| Key Action | Confirm precertification is in place before billing J9038 under any commercial Aetna plan |
Aetna Axatilimab-csfr Coverage Criteria and Medical Necessity Requirements 2025
The Aetna axatilimab-csfr coverage policy under CPB 1069 Aetna applies to commercial medical plans only. Medicare criteria are handled separately — Aetna directs providers to its Medicare Part B step therapy resource for those patients.
The single covered diagnosis under this policy is ICD-10-CM D89.811, chronic graft-versus-host disease. If your claim carries any other diagnosis code, expect a claim denial. There is no coverage pathway for acute graft-versus-host disease or other immune conditions under this bulletin.
Precertification is required — no exceptions for participating providers. Aetna axatilimab-csfr billing without an approved prior authorization will result in a denied claim. Get that auth before the drug is administered, not after.
To get prior authorization, call (866) 752-7021 or fax a Statement of Medical Necessity to (888) 267-3277. The SMN form is available through Aetna's Specialty Pharmacy Precertification portal. Build this step into your workflow before every infusion encounter.
Medical necessity documentation must support the D89.811 diagnosis. Your clinical notes need to show the patient has chronic graft-versus-host disease — not just a history of stem cell transplant or a resolved acute episode. The distinction matters at claim review.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Chronic graft-versus-host disease | Covered | J9038, D89.811, CPT 96413, 96415 | Precertification required; commercial plans only |
| Acute graft-versus-host disease | Not covered (not listed) | — | No ICD-10 or indication listed for acute cGVHD |
| Other immune/inflammatory conditions | Not covered (not listed) | — | Policy scope limited to D89.811 |
| Medicare patients | Not covered under this CPB | — | See Aetna Medicare Part B step therapy criteria separately |
Aetna Axatilimab-csfr Billing Guidelines and Action Items 2025
This policy's scope is narrow — one drug, one covered diagnosis, one HCPCS code. That simplicity works in your favor, but only if your team has the precertification and diagnosis coding locked down before claims go out.
| # | Action Item |
|---|---|
| 1 | Add J9038 to your charge capture before billing any Niktimvo infusion. HCPCS J9038 is billed per 0.1 mg of axatilimab-csfr. Calculate your units from the administered dose. Undercoding on units is a reimbursement leak that's easy to miss. |
| 2 | Pair J9038 with CPT 96413 for the first hour of infusion. If the infusion runs beyond one hour, add CPT 96415 for each additional hour. These codes are listed in the policy as related administration codes — they need to appear on the same claim as J9038. |
| 3 | Lock in prior authorization before the September 26, 2025 effective date if you have patients already on Niktimvo. Don't assume existing auths carry forward through a policy modification. Confirm with Aetna that current auths are still valid under CPB 1069 as updated. |
| 4 | Verify the diagnosis code is D89.811 — not a related code. Chronic graft-versus-host disease (D89.811) is the only ICD-10-CM code listed in this policy. Billing with D89.810 (acute cGVHD) or D89.812 (overlap syndrome) puts the claim outside the policy scope and triggers a denial. |
| 5 | Separate your commercial and Medicare workflows. This policy does not govern Medicare reimbursement. If your practice treats both commercial and Medicare cGVHD patients, your billing team needs two distinct auth and documentation pathways. Mixing them up is a common source of claim denial for high-cost infusion drugs. |
| 6 | Document medical necessity explicitly in clinical notes. Aetna's precertification process requires an SMN. Your treating physician's notes should state the cGVHD diagnosis, disease severity, and clinical rationale for axatilimab-csfr. Vague documentation gets flagged at precert review and delays treatment. |
| 7 | If you're unsure how this applies to your payer mix or patient population, talk to your compliance officer before September 26, 2025. This drug is expensive, the prior auth requirement is firm, and a missed step early in the process creates downstream billing problems that are hard to fix retroactively. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Axatilimab-csfr (Niktimvo) Under CPB 1069
Covered HCPCS Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| J9038 | HCPCS | Injection, axatilimab-csfr, 0.1 mg |
Other CPT Codes Related to CPB 1069 (Infusion Administration)
These codes cover the administration of the infusion. Bill them alongside J9038, not instead of it.
| Code | Type | Description |
|---|---|---|
| 96413 | CPT | Chemotherapy administration, IV infusion technique; up to 1 hour, single or initial substance/drug |
| 96415 | CPT | Each additional hour (list in addition to code for primary procedure) |
Note: CPT 96415 is an add-on code. You cannot bill it without 96413 as the primary code on the same claim. Most clearinghouses will reject 96415 as a standalone line — make sure your charge capture rules reflect this.
Key ICD-10-CM Diagnosis Codes
| Code | Description |
|---|---|
| D89.811 | Chronic graft-versus-host disease |
This is the only diagnosis code listed under CPB 1069. Your claim will not map to this policy under any other ICD-10-CM code. Train your coders to confirm the D89.811 designation before submission.
A Note on What's Not in This Policy
CPB 1069 Aetna is deliberately narrow. It does not list exclusions or non-covered indications in the usual sense — it simply defines one covered condition (D89.811) and one covered drug (J9038). Anything outside that combination is out of scope by omission.
The real issue here is that specialty drug policies like this one often expand over time. Axatilimab-csfr received FDA approval for cGVHD, and that's currently the policy's entire scope. Watch for future modifications to CPB 1069 that may add step therapy requirements, line-of-therapy criteria, or response assessment benchmarks. That's the pattern Aetna follows with other specialty infusion policies — narrow at launch, more restrictive at first revision.
If your practice is building a cGVHD treatment program around Niktimvo, set a calendar reminder to recheck this policy at the six-month mark. Policy modifications on newly approved specialty drugs tend to arrive faster than on established therapies.
Get the Full Picture for CPT 96413
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.